Düsseldorf - The morbidity-related total remuneration (MGV) will rise in 2013 in North Rhine by 128 million euros or 5.15 percent. The health insurance companies of the region have agreed on this. “We achieved good result with the real increase of 5.15 percent, which, analogous to the agreement at the federal level, could also be expected to increase the volume of psychotherapeutic services and the increase in the reference point value for individual services outside the MGV,” said Peter Potthoff, CEO of KV Nordrhein.
He was satisfied because the new plus in total remuneration at least partially compensated for the disadvantage of North Rhine in terms of outpatient medical care. For the outpatient care of patients in the Rhineland, an average of 352 euros per patient and year is now available. "In 2012 our value was still 334 euros - so everyone can see that we have made significant step forward," says Bernhard Brautmeier, board member of KV Nordrhein.
The increase is spread over several Areas and does not affect all doctor groups in the same way. The reason for this are the requirements of the Extended Evaluation Committee at federal level. 23 million euros are available in North Rhine-Westphalia to finance the treatment of multimorbid patients with three or more chronic diseases, 28.8 million euros flow into primary care in the general practitioner and specialist field.
All resident doctors benefit from the increase in the orientation point value already agreed at the federal level by 0.9 percent from 3.5048 to 3.5363 cents, which is fee increase for North Rhine-Westphalia of also 23 million euros. In addition, the central negotiation result is the further development of the MGV this year by 2.15 percent - this corresponds to an amount of 53.2 million euros.
The health insurance companies also rated the conclusion positively. “The negotiations were always constructive and effective. This is good basis for working together on improving outpatient medical care for the people in North Rhine, ”said Andreas Hustadt from the Association of Substitute Funds. Günter Waltermann, chairman of the board of AOK Rheinland / Hamburg, described the result as an “investment in the future”. The higher expenditures should benefit the patients as noticeably better care.